ZGNX - Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and Secretary, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, being held October 2-3, 2018, in New York, NY.
| Zogenix Presentation Details |
| Date: |
| Tuesday, October 2, 2018 |
| Time: |
| 10:30 AM Eastern Time / 7:30 AM Pacific Time |
| Location: |
| New York, NY - Lotte New York Palace Hotel |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
About Zogenix
Zogenix (Nasdaq: ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Media: David Polk
Senior Media Relations Strategist, Syneos Health
310-309-1029 | david.polk@syneoshealth.com